TARS — Tarsus Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1819790 ·
Last close
$78.20
Market Cap
$3.86B
52W High
$91.53
52W Low
$53.89
ADV30
959,142
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 194,569,000 180,675,000 -663,714,000 -668,334,000 505,499,000 136,530,000 401,470,000
Jun 2026 173,912,000 161,799,000 -19,908,000 -18,551,000 611,142,000 204,595,000 264,410,000
Mar 2026 162,054,000 152,658,000 -6,122,000 -6,967,000 581,135,000 102,192,000 232,184,000
Dec 2025 151,668,000 140,741,000 -7,976,000 -8,373,000 562,158,000 183,641,000 218,732,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$49,899,000
Investing CF
$-160,901,000
Financing CF
$134,627,000
CapEx
$-54,748,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.19
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,120,480,000
Inventory
$5,159,000
Receivables
$102,106,000
ST Investments
$173,082,000
EBIT TTM
$-682,425,000
Pretax Income TTM
$-690,456,000
Interest Exp TTM
$8,031,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$682,203,008
EBITDA
$-62,637,000
Free Cash Flow
$79,938,128
Enterprise Value
$3,162,180,864
Total Cash
$309,612,000
Total Debt
$89,432,000
Shares Out
49,305,552
Trailing EPS
$-15.86
Book Value
$2.11
ROE
-319.8%
ROA
-7.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 451,360,000 -70,969,000 -66,418,000 562,158,000 218,732,000 343,426,000 -12,451,000
Dec 2024 182,953,000 -120,569,000 -115,554,000 376,991,000 152,457,000 224,534,000 -83,027,000
Dec 2023 17,447,000 -143,158,000 -135,893,000 265,491,000 68,503,000 196,988,000 -117,493,000
Dec 2022 25,816,000 -62,712,000 -62,091,000 227,863,000 34,963,000 192,900,000 -49,030,000

TTM Snapshot

Revenues TTM
$606,331,000
NetIncome TTM
$-46,476,000
OpCashFlow TTM
—
Assets (Latest)
$611,142,000
Forward EPS
$0.21

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $67.50 · spot: $75.95 · call volume: 218 · put volume: 23

Peers — same industry

TickerNameMarket CapLastDaily %
CRSP CRISPR Therapeutics AG $3.89B $40.15 —
RLAY Relay Therapeutics, Inc. $3.64B $16.47 —
IOVA IOVANCE BIOTHERAPEUTICS, INC. $3.48B $7.53 —
ADPT Adaptive Biotechnologies Corp $4.61B $28.49 —
ADMA ADMA BIOLOGICS, INC. $3.02B $13.63 —

News headlines (Yahoo Finance, 1h cache)

Is Raised Revenue Outlook Altering The Investment Case For Tarsus Pharmaceuticals (TARS)?
2026-11-06 14:11 · Yahoo
Is Tarsus Pharmaceuticals (TARS) Below Fair Value On Cash Flow?
2026-11-06 06:10 · Yahoo
Tarsus Pharmaceuticals (TARS) Could Be 31% Undervalued Following Record Q3 Sales
2026-11-05 22:09 · Yahoo
Tarsus to Participate in Upcoming Investor Conferences
2026-11-05 21:30 · Yahoo
Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ...
2026-11-05 03:04 · Yahoo
Tarsus (TARS) Q3 2026 Earnings Call Transcript
2026-11-04 16:16 · Yahoo
Tarsus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
2026-11-04 03:14 · Yahoo
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
2026-11-03 23:55 · Yahoo
Tarsus Reports Third Quarter 2026 Financial Results
2026-11-03 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.